[Purine metabolism in patients with renal failure].
Hosoya
Tatsuo
T
Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine.
Ohno
Iwao
I
Uetake
Daijiro
D
Saikawa
Hajime
H
D000493:Allopurinol / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D019271:Hypoxanthine / Q000378:metabolism; D007668:Kidney / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D011687:Purines / Q000378:metabolism*; D006435:Renal Dialysis / Q000009:adverse effects; D014527:Uric Acid / Q000378:metabolism; D019820:Xanthine / Q000378:metabolism
D000963:Antimetabolites; D011687:Purines; D019820:Xanthine; D014527:Uric Acid; D019271:Hypoxanthine; D000493:Allopurinol; C030985:purine